Experience of Simultaneous Pancreas and Kidney Transplantation in Seoul National University Hospital.
- Author:
Jae Woo PARK
1
;
Jongwon HA
;
Jung Hoon LEE
;
Jin Mo KANG
;
Sun Kyung JUNG
;
Eun Man KIM
;
Ho Sun LEE
;
Yon Su KIM
;
Young Min CHO
;
Kyong Soo PARK
;
Curie AHN
;
Sang Joon KIM
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Korea. jwhamd@snu.ac.kr Department of Internal Medicine, Seoul National University College of Medicine, Korea. Transplantation Center, Seoul National University Hospital, Korea. The Tra
- Publication Type:Original Article
- Keywords:
Pancreas transplantation;
Kidney transplantation;
Diabetes mellitus;
ESRD (end-stage renal disease);
Immunosuppressive agents
- MeSH:
Blood Glucose;
Diabetes Mellitus;
Follow-Up Studies;
Humans;
Immunosuppressive Agents;
Insulin;
Kidney Transplantation*;
Kidney*;
Medical Records;
Mortality;
Pancreas Transplantation;
Pancreas*;
Pancreatectomy;
Pancreatitis, Graft;
Reference Values;
Retrospective Studies;
Seoul*;
Transplants
- From:The Journal of the Korean Society for Transplantation
2006;20(2):181-186
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Purpose: Aim of this study is to review the simultaneous pancreas and kidney transplantation (SPK) cases performed in Seoul National University Hospital for DM nephropathy patients. Methods: Medical records of the SPK recipients from April 2002 to February 2006 were reviewed and analyzed retrospectively. Results: There were 10 cases of SPK transplantation in SNUH from April 2002 to February 2006, which were composed of 8 type II DM patients and 2 type I DM patients. We experienced 1 operative mortality case and 3 acute rejection cases. All the acute rejection cases were recovered by steroid pulse therapy. We performed two graft pancreatectomy operations due to CMV infection followed by duodenal perforation and severe graft pancreatitis with pancreatic leakage. With the exception of 1 mortality case and 2 graft loss cases, all 7 patients stopped insulin and oral hypoglycemic agent and are keeping blood glucose level within normal range. Conclusion: Although patient follow-up is limited up to four years, SPK recipients are free from insulin use and show good graft functions. SPK could be a good treatment modality for insulin dependent type II DM nephropathy patients.
